Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must have chronic hepatitis C infection (genotype 1) with HCV RNA level \>= 1000 IU/mL~* Patient must have failed at least 1 prior course of Peg-IFN/RBV therapy (standard treatment)~* Patient must be willing to use 2 effective methods of birth control for up to 7 months after last dose of study medication~Exclusion Criteria:~* Patient is a previous non-responder that is classified as a viral breakthrough case~* Patient is infected with Hepatitis C virus, genotype 1, exhibiting more than one subtype~* Patient has Hepatitis C virus, genotype 1, and exhibits co-infection with any other genotype~* Evidence of decompensated liver disease~* Patient has condition that requires use of systemic corticosteroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Group A: T12/PR48 (Type: EXPERIMENTAL): Participants will receive 12 weeks of 750 mg telaprevir eight hourly followed by 4 weeks of Placebo in combination with 48 weeks of Peg-IFN-alfa-2a and ribavirin at standard doses.
- Group B: T12(DS)/PR48 (Type: EXPERIMENTAL): Participants will receive 4 weeks of Placebo followed by 12 weeks of 750 mg telaprevir eight hourly in combination with 48 weeks of Peg-IFN-alfa-2a and ribavirin at standard doses.
- Group C: Pbo/PR48 (Type: EXPERIMENTAL): Participants will receive placebo in combination with Peg- IFN-alfa-2a and ribavirin for 16 weeks. Participants will receive Peg- IFN-alfa-2a and ribavirin for next 32 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).